<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02190318</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-RENAL-IIS-2013-029</org_study_id>
    <nct_id>NCT02190318</nct_id>
  </id_info>
  <brief_title>Residual Renal Function Preservation in Peritoneal Dialysis Patients</brief_title>
  <official_title>The Effects of Losartan and Spironolactone on Residual Renal Function Preservation in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <brief_summary>
    <textblock>
      Aldosterone blockade is useful in preserving residual renal function in patients on PD.The
      long term efficacy of dual blockade of the RAAS is better than monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Residual renal function has been proven to contribute to improved survival and quality of
      life of dialysis patients. It is now recognized as an important factor in the prognosis of
      PD.The RAAS system is involved in the development of renal diseases. Angiotensin II and
      aldosterone are vital in this process. The beneficial effect of angiotensin-converting enzyme
      inhibitor or angiotensin receptor blocker on residual renal function has been demonstrated in
      peritoneal dialysis patients. Unfortunately, neither ACE inhibition nor angiotensin receptor
      blocker fully supprsses aldosterone production. Now much focus has been placed on aldosterone
      antagonist.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>residual renal function of peritoneal dialysis patients</measure>
    <time_frame>From date of randomization until the date of dropping out of the study or death from any cause, whichever came first, assessed up to 12 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>peritoneal membrane function</measure>
    <time_frame>From date of randomization until the date of dropping out of the study or death from any cause, whichever came first, assessed up to 12 months.</time_frame>
    <description>peritoneal membrane function is measured by peritoneal equilibration test to test the type of peritoneal transport. Briefly, a standard 4-hour dwell period was used (first exchange of the day), using a 2.5% glucose concentration 2-L volume exchange. The patient used their usual overnight dialysis regimen, and both the overnight and test drainage volumes were measured.The dialysate:plasma ratio of creatinine at the completion of the 4-hour dwell period (D/Pcreat) was used as the estimate of low-molecular-weight solute transport.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Chronic Renal Disease</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan is taken orally 100mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>spirolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>spirolactone is taken orally 20mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>losartan in combination with spirolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan is taken orally 100mg/d and spirolactone is taken orally 20mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>patients with antihypertensives besides ACEI/ARBs and spirolactone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_label>losartan in combination with spirolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spirolactone</intervention_name>
    <arm_group_label>spirolactone</arm_group_label>
    <arm_group_label>losartan in combination with spirolactone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blank control</intervention_name>
    <arm_group_label>blank control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who having been on PD continuously for one month, urine volume＞600 ml/d,
             residual renal function＞2ml/min/1.73m2, blood pressure＞120/70mmHg, serum potassium
             levels＜5.5mmol/l, stable clinical condition.

        Exclusion Criteria:

          -  Patients with infectious systemic disease, peritonitis during the preceding 1 month,
             who had taken ACEI/ARBs in the 3 preceding months, spirolactone in the 2 preceding
             weeks, intolerance to ACEI/ARBs, CHF, MI, malignant hypertension and stroke within the
             preceding 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Liu, MD,phD</last_name>
    <phone>86-0731-85292057</phone>
    <email>liuh0618@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Liu, MD,phD</last_name>
      <phone>86-0731-85292057</phone>
      <email>liuh0618@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong Liu, MD,phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>July 31, 2014</last_update_submitted>
  <last_update_submitted_qc>July 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Hong Liu</investigator_full_name>
    <investigator_title>deputy director of nephrology department</investigator_title>
  </responsible_party>
  <keyword>peritoneal dialysis；</keyword>
  <keyword>residual renal function；</keyword>
  <keyword>RAAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

